Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies

Clicks: 363
ID: 115318
1998
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #16 of 83 articles by views in The Journal of antimicrobial chemotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Modern chemotherapy for lymphoma and solid tissue malignancy is most frequently administered in a cyclical fashion on an outpatient basis over many months. During this time patients have a significant risk of developing severe neutropenia due to the myelotoxic effects of the treatment regimens; this …
Reference Key
ej1998theinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bow EJ;;
Journal The Journal of antimicrobial chemotherapy
Year 1998
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9688446
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review animals humans pubmed abstract nih national institutes of health national library of medicine risk fever / etiology* neoplasms / immunology* lymphoma / drug therapy neoplasms / drug therapy* antineoplastic agents / adverse effects* pmid:9688446 doi:10.1093/jac/41.suppl_4.1 e j bow lymphoma / immunology neutropenia / etiology* neutropenia / immunology opportunistic infections* / immunology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.